In this issue:
EXCEED: Secukinumab and adalimumab have similar musculoskeletal efficacy
Guselkumab efficacious for sacroiliac axial disease manifestations
Humoral response to Pfizer COVID vaccine
Tenderness in established arthritis may indicate joint damage, not inflammation
Lower ACR response rates to TNF inhibition in patients with high levels of fatigue
TNF inhibitors effective in real-world for enthesitis in axSpA
Is axial PsA a distinct phenotype between axSpA and pure peripheral PsA?
Secukinumab and ustekinumab treatment in PsA
Adalimumab patient support program increases adherence and reduces opioid use
Predictors of hospitalisation in patients with rheumatic disease and COVID-19 in Ireland
Please login below to download this issue (PDF)